In the US, breast cancer is striking with startling numbers, from an estimated 297,790 new invasive diagnoses and 43,700 projected deaths in 2023 to a 5 year survival that ranges from 99% for localized disease to just 30% for distant cancer, so in this post we break down what those figures mean right now and why early detection, accurate staging, and equitable care matter.
Key Takeaways
- In the United States, an estimated 297,790 new cases of invasive breast cancer were diagnosed in 2023
- In the United States, an estimated 43,700 deaths from breast cancer were projected for 2023
- In the United States, the 5-year relative survival rate for breast cancer is 91% (diagnosed 2014–2020)
- The most common type of breast cancer is invasive ductal carcinoma, accounting for 70% to 80% of cases
- Invasive lobular carcinoma accounts for 10% to 15% of invasive breast cancers
- Ductal carcinoma in situ (DCIS) accounts for about 20% of new breast cancer diagnoses in the United States
- Screening mammography can detect breast cancer before symptoms
- The USPSTF recommends biennial screening mammography for women aged 40 to 74
- The USPSTF recommends screening mammography for women aged 40 to 74 with individual decision-making
- Tamoxifen is typically used for ER-positive breast cancer
- Aromatase inhibitors are used in postmenopausal patients with ER-positive breast cancer
- Trastuzumab is a targeted therapy for HER2-positive breast cancer
- The proportion of breast cancers that are ER-positive is about 70%
- The proportion of breast cancers that are PR-positive is a substantial fraction
- HER2-positive breast cancer accounts for about 15%–20% of cases
Breast cancer remains common and deadly, with better survival when localized.
Incidence & Mortality
1In the United States, an estimated 297,790 new cases of invasive breast cancer were diagnosed in 2023[1]
Verified2In the United States, an estimated 43,700 deaths from breast cancer were projected for 2023[1]
Verified3In the United States, the 5-year relative survival rate for breast cancer is 91% (diagnosed 2014–2020)[1]
Verified4In the United States, the 5-year relative survival rate for localized breast cancer is 99%[1]
Directional5In the United States, the 5-year relative survival rate for regional breast cancer is 86%[1]
Single source6In the United States, the 5-year relative survival rate for distant breast cancer is 30%[1]
Verified7In the United States, breast cancer is estimated to account for 30% of all new cancer cases in women[2]
Verified8In the United States, breast cancer is estimated to account for 28% of new cancer cases among women[2]
Verified9In the United States, an estimated 1 in 8 women will be diagnosed with breast cancer over the course of her lifetime[2]
Directional10In the United States, an estimated 1 in 42 women will die of breast cancer[2]
Single source11In the United States, breast cancer accounts for about 15% of all cancer deaths in women[3]
Verified12The age-adjusted incidence rate of female breast cancer in the United States (all races) was 128.9 per 100,000 in 2020[1]
Verified13The age-adjusted incidence rate of breast cancer in the United States (all races) was 131.8 per 100,000 in 2019[1]
Verified14The age-adjusted incidence rate of breast cancer in the United States (all races) was 127.5 per 100,000 in 2021[1]
Directional15The age-adjusted mortality rate of breast cancer in the United States (all races) was 23.1 per 100,000 in 2020[1]
Single source16The age-adjusted mortality rate of breast cancer in the United States (all races) was 22.9 per 100,000 in 2019[1]
Verified17The age-adjusted mortality rate of breast cancer in the United States (all races) was 22.4 per 100,000 in 2021[1]
Verified18In the United States, about 63% of breast cancers are diagnosed at the localized stage[1]
Verified19In the United States, about 30% of breast cancers are diagnosed at the regional stage[1]
Directional20In the United States, about 6% of breast cancers are diagnosed at the distant stage[1]
Single source21In the United States, about 1% of breast cancers are diagnosed at an unknown stage[1]
Verified22In the United States, in 2023, an estimated 55,720 new cases of in situ breast cancer (DCIS) were expected[1]
Verified23In the United States, in 2023, an estimated 4,640 deaths were expected from breast cancer[1]
Verified24Breast cancer incidence rates in the United States are higher in Black women than in White women[4]
Directional25In the United States, breast cancer death rates are higher for Black women than for White women[4]
Single source26In the United States, breast cancer survival is higher for White women than for Black women[4]
Verified27Globally, there were 2.3 million new cases of breast cancer in 2020[5]
Verified28Globally, there were 685,000 deaths from breast cancer in 2020[5]
Verified29In 2020, breast cancer had the highest number of new cancer cases among cancers[5]
Directional30In 2020, breast cancer was the second-leading cause of cancer death worldwide[5]
Single source31The International Agency for Research on Cancer estimated 7.8 million deaths from cancer worldwide in 2020[5]
Verified32In Europe, breast cancer is the most frequently diagnosed cancer in women with 202,000 deaths in 2020[6]
Verified33In Europe, breast cancer accounts for 1 in 7 cancer diagnoses in women[6]
Verified34In Europe, the 5-year survival rate for breast cancer is about 85%[6]
Directional35The European Commission report indicates that breast cancer prevalence is about 8.1 million people[6]
Single source36In the US SEER program, there were 287,850 new breast cancer cases in 2019[7]
Verified37In the US SEER program, the breast cancer mortality rate declined 1.5% per year from 2002 to 2018[1]
Verified38In the United States, the breast cancer death rate dropped by 43% from 1989 to 2017[3]
Verified39In the United States, deaths from breast cancer have decreased by 1.8% per year for women from 2014 to 2019[4]
Directional40In the United States, the number of breast cancer survivors is about 3.8 million[3]
Single source41In the United States, the number of breast cancer survivors is projected to increase to about 4.5 million by 2030[3]
VerifiedIncidence & Mortality Interpretation
In the United States, breast cancer is both alarmingly common, with nearly 298,000 new invasive cases and about 1 in 8 women diagnosed by lifetime, and also a genuine survival story, since overall 5 year relative survival is 91 percent and localized disease is 99 percent, yet it still takes about 43,700 projected lives in 2023 and, worst of all, distant stage survival plummets to 30 percent, while disparities persist and global numbers underline the scale of the problem, even as progress and declining death rates hint that better detection, treatment, and equity can keep turning the odds.
Risk, Genetics & Subtypes
1The most common type of breast cancer is invasive ductal carcinoma, accounting for 70% to 80% of cases[8]
Verified2Invasive lobular carcinoma accounts for 10% to 15% of invasive breast cancers[8]
Verified3Ductal carcinoma in situ (DCIS) accounts for about 20% of new breast cancer diagnoses in the United States[8]
Verified4Triple-negative breast cancer accounts for about 10% to 20% of all breast cancers[9]
Directional5HER2-positive breast cancer accounts for about 15% to 20% of breast cancers[9]
Single source6Hormone receptor–positive (ER-positive and/or PR-positive) breast cancer makes up about 70% of breast cancers[9]
Verified7Luminal A breast cancer is the most common molecular subtype, accounting for 30% to 60% of cases[10]
Verified8Luminal B breast cancer accounts for 10% to 20% of cases[10]
Verified9HER2-enriched breast cancer accounts for about 10% to 15% of cases[10]
Directional10Basal-like breast cancer overlaps with triple-negative breast cancer and is associated with higher relapse risk[10]
Single source11BRCA1 mutations account for about 45% to 65% of hereditary breast cancers[11]
Verified12BRCA2 mutations account for about 25% to 35% of hereditary breast cancers[11]
Verified13About 5% to 10% of breast cancers are hereditary, often linked to gene mutations like BRCA1 and BRCA2[12]
Verified14Women with a BRCA1 mutation have about a 65% lifetime risk of developing breast cancer[12]
Directional15Women with a BRCA2 mutation have about a 45% lifetime risk of developing breast cancer[12]
Single source16Lifetime risk of breast cancer for women with both BRCA1 and BRCA2 mutations is higher[12]
Verified17A first-degree relative with breast cancer increases risk[13]
Verified18Having a mother, sister, or daughter with breast cancer nearly doubles risk[13]
Verified19Risk increases with age; the majority of breast cancers occur after age 50[2]
Directional20The median age at diagnosis of breast cancer in the US is 62[4]
Single source21Men account for about 1% of all breast cancer cases[1]
Verified22Approximately 99% of breast cancer occurs in women[1]
Verified23Having a first period before age 12 is a risk factor associated with increased breast cancer risk[13]
Verified24Having menopause after age 55 is a risk factor for increased breast cancer risk[13]
Directional25Not having children or having first child after age 30 increases risk[13]
Single source26Breastfeeding for at least 6 months is associated with reduced breast cancer risk[13]
Verified27Alcohol consumption increases risk; even 1 drink per day is associated with increased risk[14]
Verified28Overweight and obesity after menopause increase breast cancer risk[15]
Verified29Physical activity reduces risk of breast cancer[16]
Directional30Women who took hormone therapy (combined estrogen and progestin) have increased breast cancer risk[17]
Single source31Prior radiation to chest at a young age increases breast cancer risk[18]
Verified32A BRCA1 or BRCA2 mutation also increases risk of ovarian cancer[12]
Verified33About 1% to 2% of breast cancers are due to mutations in TP53 (Li-Fraumeni syndrome)[11]
Verified34About 1% to 2% of breast cancers are due to mutations in PTEN (Cowden syndrome)[11]
Directional35About 2% to 3% of breast cancers are due to mutations in PALB2[11]
Single source36About 4% to 6% of breast cancers are due to mutations in CHEK2[11]
Verified37Individuals with atypical hyperplasia have a higher risk of developing breast cancer compared with those without atypical hyperplasia[1]
Verified38Women with lobular carcinoma in situ (LCIS) have increased risk of developing invasive breast cancer[1]
Verified39The risk of breast cancer increases with family history of breast cancer in multiple relatives[19]
Directional40Women with a family history of breast cancer in a first-degree relative have about twice the risk compared with women without such a history[19]
Single source41About 10% of breast cancers are diagnosed in women younger than 45[1]
VerifiedRisk, Genetics & Subtypes Interpretation
Breast cancer statistics read like a plot twist: most cases are invasive ductal carcinoma and hormone receptor positive, but the biology, genetics, and life stage factors stack up in complicated ways, from triple negative and HER2 positive subtypes to BRCA1 and BRCA2 hereditary risks, with the strongest “quiet villains” being aging and reproductive and lifestyle factors like early periods, late menopause, fewer or later pregnancies, alcohol, excess weight after menopause, and lack of physical activity.
Screening & Diagnosis
1Screening mammography can detect breast cancer before symptoms[20]
Verified2The USPSTF recommends biennial screening mammography for women aged 40 to 74[21]
Verified3The USPSTF recommends screening mammography for women aged 40 to 74 with individual decision-making[21]
Verified4The USPSTF recommendation specifies biennial screening mammography (every 2 years) for average-risk women aged 40 to 74[21]
Directional5For women at high risk, screening with MRI and mammography may be recommended annually[22]
Single source6The American Cancer Society recommends that women at high risk get a breast MRI and a mammogram every year[23]
Verified7The American Cancer Society recommends that average-risk women start annual mammograms at age 45[23]
Verified8The American Cancer Society recommends annual mammograms at age 45 to 54[23]
Verified9The American Cancer Society recommends mammograms every year or every 2 years at age 55 and older[23]
Directional10Breast self-exam is not recommended as a screening test by USPSTF for all women[21]
Single source11Clinical breast exam is not recommended as a screening test by USPSTF for average-risk women[21]
Verified12For high-risk women, MRI screening is recommended in addition to mammography[19]
Verified13Diagnostic mammography is used to evaluate abnormal screening mammogram results[20]
Verified14Ultrasound can be used to evaluate lumps or abnormal mammogram findings[20]
Directional15Breast MRI is used to evaluate some abnormal mammogram results and for high-risk screening[20]
Single source16The sensitivity of mammography varies by age and breast density[20]
Verified17In the US, about 50% of women have dense breast tissue[20]
Verified18Dense breast tissue is associated with higher risk of breast cancer and reduced mammography sensitivity[20]
Verified19Breast biopsy is required to confirm diagnosis of breast cancer[24]
Directional20Core needle biopsy is often used to obtain tissue samples for diagnosis[24]
Single source21Fine needle aspiration may be used in some cases to sample fluid or tissue[24]
Verified22Sentinel lymph node biopsy is used to stage early breast cancer[25]
Verified23Axillary lymph node dissection is used in some cases when more extensive nodal surgery is needed[25]
Verified24PET/CT may be used to evaluate spread in some cases of breast cancer[26]
Directional25Stage determines treatment and prognosis[27]
Single source26TNM staging uses tumor size, lymph node involvement, and metastasis[27]
Verified27Breast cancer can be staged from 0 to IV[27]
Verified28Grade describes how abnormal the cancer cells look under a microscope[1]
Verified29Tumor markers (ER, PR, HER2) help guide treatment decisions[28]
Directional30ER-positive tumors have estrogen receptors on cancer cells[28]
Single source31PR-positive tumors have progesterone receptors on cancer cells[28]
Verified32HER2-positive tumors have higher-than-normal HER2 protein levels[28]
Verified33Triple-negative breast cancer is defined by lack of ER, PR, and HER2 expression[28]
Verified34Ki-67 is used to estimate how quickly cancer cells are dividing[28]
Directional35A pathologic complete response (pCR) means no remaining invasive cancer in the breast/lymph nodes after neoadjuvant therapy[29]
Single source36The term “invasive carcinoma” refers to cancer that has spread beyond the original duct or lobule[30]
VerifiedScreening & Diagnosis Interpretation
Breast cancer screening is basically the medical equivalent of catching a suspect before they make a scene, with major groups agreeing that many women aged 40 to 74 benefit from mammograms typically every one to two years, higher risk patients may need MRI as well, suspicious findings are confirmed with biopsy, and once cancer is diagnosed clinicians use staging, grade, receptor status like ER, PR, and HER2, and measures like Ki 67 to map the disease from stage 0 through IV and choose treatment from there, because in the end the cells and their behavior tell the plot.
Treatment & Clinical Outcomes
1Tamoxifen is typically used for ER-positive breast cancer[31]
Verified2Aromatase inhibitors are used in postmenopausal patients with ER-positive breast cancer[31]
Verified3Trastuzumab is a targeted therapy for HER2-positive breast cancer[32]
Verified4Pertuzumab is used with trastuzumab for HER2-positive breast cancer in some settings[32]
Directional5CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) are used in HR-positive/HER2-negative metastatic breast cancer[33]
Single source6Everolimus is used with exemestane for certain HR-positive metastatic breast cancers[33]
Verified7PARP inhibitors (e.g., olaparib) are used in some patients with germline BRCA-mutated HER2-negative metastatic breast cancer[34]
Verified8Chemotherapy is used in many subtypes, including triple-negative breast cancer[31]
Verified9Radiation therapy is used after breast-conserving surgery[31]
Directional10Mastectomy is an option for breast cancer treatment in certain cases[31]
Single source11Sentinel lymph node biopsy is often used to assess axillary nodes[25]
Verified12Overall survival varies strongly by stage at diagnosis[1]
Verified13In the US, 5-year relative survival for localized breast cancer is 99%[1]
Verified14In the US, 5-year relative survival for regional breast cancer is 86%[1]
Directional15In the US, 5-year relative survival for distant breast cancer is 30%[1]
Single source16In the US, 5-year relative survival for all breast cancer is 91%[1]
Verified17Neoadjuvant therapy is treatment given before surgery in some cases[35]
Verified18Pathologic complete response (pCR) can predict improved outcomes in some cancers after neoadjuvant therapy[29]
Verified19For HR-positive metastatic breast cancer, endocrine therapy is a primary treatment approach[31]
Directional20For HER2-positive metastatic breast cancer, anti-HER2 therapy is central[32]
Single source21For triple-negative metastatic breast cancer, chemotherapy is often used[36]
Verified22Immunotherapy (e.g., pembrolizumab) can be used for some PD-L1–positive advanced triple-negative breast cancer[36]
Verified23Pembrolizumab is given with chemotherapy in PD-L1–positive advanced triple-negative breast cancer in the KEYNOTE-355 context[36]
Verified24The median duration of response and survival vary by regimen and disease setting[36]
Directional25For HER2-positive early breast cancer, dual HER2 blockade with trastuzumab plus pertuzumab may be used[32]
Single source26For ER-positive early breast cancer, endocrine therapy can reduce recurrence risk[31]
Verified27Prophylactic surgery is not standard for all patients, but risk-reducing mastectomy is considered for high-risk patients[37]
Verified28Risk-reducing mastectomy can reduce breast cancer risk substantially in high-risk individuals[37]
Verified29Reconstruction may be done after mastectomy[38]
Directional30In general, breast reconstruction options include implants or autologous tissue[38]
Single source31Treatment choice depends on tumor biology (ER/PR/HER2), grade, and stage[31]
Verified32Surgical margins matter for breast-conserving therapy[39]
VerifiedTreatment & Clinical Outcomes Interpretation
Breast cancer care today is a stage-based choose-your-own-adventure where tumor biology (ER, PR, HER2, and BRCA status) dictates whether you’re looking at endocrine drugs, anti-HER2 combos, targeted inhibitors, chemotherapy, radiation, or immunotherapy, and while survival is excellent when caught localized (99% 5-year relative survival in the US) it drops sharply with distance (30% for distant disease), making early detection and right-timed treatment not just smart, but quietly life-defining.
Epidemiology, Risk Factors & Burden
1The proportion of breast cancers that are ER-positive is about 70%[28]
Verified2The proportion of breast cancers that are PR-positive is a substantial fraction[28]
Verified3HER2-positive breast cancer accounts for about 15%–20% of cases[28]
Verified4Triple-negative breast cancer accounts for 10%–20% of breast cancers[28]
Directional5Breast cancer risk is higher in women with more breast tissue density[20]
Single source6Approximately 50% of women have dense breasts[20]
Verified7Dense breast tissue can increase the risk of breast cancer and lower mammography sensitivity[20]
Verified8Alcohol consumption is a modifiable risk factor for breast cancer[19]
Verified9Physical inactivity is associated with increased risk of breast cancer[19]
Directional10Overweight and obesity increase breast cancer risk after menopause[19]
Single source11Postmenopausal hormone therapy (combined estrogen and progestin) increases breast cancer risk[19]
Verified12Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast cancer[19]
Verified13In the US, Black women have a higher breast cancer incidence rate than White women[4]
Verified14In the US, Black women have a higher breast cancer death rate than White women[4]
Directional15American Indian/Alaska Native women have a lower breast cancer incidence rate than White women[4]
Single source16Asian/Pacific Islander women have lower breast cancer incidence rates than White women[4]
Verified17Hispanic women have breast cancer mortality rates lower than non-Hispanic White women[4]
Verified18Incidence rates have stabilized in recent years in the US for breast cancer overall[4]
Verified19Death rates have been decreasing in the US[4]
Directional20Breast cancer survival differs by race/ethnicity in the US[4]
Single source21Breast cancer is the most common cancer among women in the US (excluding skin cancers)[40]
Verified22Breast cancer is a leading cause of cancer death among women in the US[40]
Verified23In 2020, breast cancer represented 24.5% of all female cancer cases globally[5]
Verified24In 2020, breast cancer represented 15.5% of all cancer deaths in women globally[5]
Directional25In 2020, breast cancer represented 11.7% of all cancer cases worldwide[5]
Single source26In 2020, breast cancer represented 6.9% of all cancer deaths worldwide[5]
Verified27Globally, about 1 in 5 cancer cases in women is breast cancer[5]
Verified28Globally, about 1 in 6 cancer deaths in women is from breast cancer[5]
Verified29Mammography screening can reduce breast cancer mortality in randomized trials[20]
Directional30Screening mammography detects cancers earlier than diagnosis based on symptoms[20]
Single source31In the US, there are substantial disparities in screening rates by race and insurance status[4]
Verified32In the US, screening rates among women aged 50–74 are around 70%[4]
Verified33In the US, screening rates among women aged 40–49 are lower than among women aged 50–74[4]
Verified34In the US, many women do not follow recommended screening schedules[4]
Directional35Breast cancer incidence rises with age and peaks in the 70–74 age group[1]
Single source36SEER shows that breast cancer incidence increases with age[1]
Verified37In SEER, breast cancer incidence is highest in people aged 70–74[1]
Verified38Breast cancer incidence is lower in younger age groups[1]
Verified39In the US, the median age at diagnosis is 62 years[4]
Directional40In the US, the median age at death from breast cancer is 68 years[4]
Single source41In the US, the prevalence of breast cancer is about 3.8 million survivors[3]
Verified42The burden of breast cancer includes millions of survivors[3]
VerifiedEpidemiology, Risk Factors & Burden Interpretation
Breast cancer is often an ER and PR positive disease that mostly grows in predictable, treatable pathways, yet it is still common, deadly enough to lead cancer deaths among US women, and shaped by biology, lifestyle, screening access, and racial and global inequities, with dense breasts and missed mammograms quietly raising the odds while modifiable factors like alcohol, inactivity, and postmenopausal weight fight back in the background.
References
- 1seer.cancer.gov/statfacts/html/breast.html
- 7seer.cancer.gov/csr/1975_2020/ (linking context)
- 2cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
- 3cancer.org/cancer/types/breast-cancer/about/key-statistics.html
- 8cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer.html
- 23cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-cancer-early-detection-guidelines.html
- 4cdc.gov/cancer/breast/statistics/index.htm
- 11cdc.gov/genomics/education/learn/online/module-2/lesson4.html
- 19cdc.gov/cancer/breast/basic_info/risk_factors.htm
- 20cdc.gov/cancer/breast/basic_info/screening.htm
- 24cdc.gov/cancer/breast/basic_info/diagnosis.htm
- 40cdc.gov/cancer/breast/basic_info/index.htm
- 5gco.iarc.fr/today/home
- 6ec.europa.eu/jrc/en/health-safety-and-environment/reports/breast-cancer
- 9cancer.gov/types/breast/risk-and-breast-cancer
- 10cancer.gov/types/breast/patient/breast-subtypes-pdq
- 12cancer.gov/types/breast/patient/brca-fact-sheet
- 13cancer.gov/types/breast/patient/breast-risk-fact-sheet
- 14cancer.gov/about-cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet
- 15cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet
- 16cancer.gov/about-cancer/causes-prevention/risk/physical-activity/physical-activity-fact-sheet
- 17cancer.gov/about-cancer/causes-prevention/risk/hormones/hormone-therapy-fact-sheet
- 18cancer.gov/about-cancer/causes-prevention/risk/radiation/radiation-risk
- 22cancer.gov/types/breast/risk-assessment/screening
- 25cancer.gov/about-cancer/diagnosis-staging/lymph-node-sentinel
- 26cancer.gov/about-cancer/diagnosis-staging/tests/pet-ct
- 27cancer.gov/about-cancer/diagnosis-staging/staging
- 28cancer.gov/types/breast/patient/breast-types
- 29cancer.gov/publications/dictionaries/cancer-terms/def/pathologic-complete-response
- 30cancer.gov/publications/dictionaries/cancer-terms/def/invasive-carcinoma
- 31cancer.gov/types/breast/patient/treatment-breast
- 32cancer.gov/types/breast/patient/treatment-breast-h2
- 33cancer.gov/types/breast/patient/breast-cancer-tdqc
- 34cancer.gov/types/breast/patient/brca-germline
- 35cancer.gov/publications/dictionaries/cancer-terms/def/neoadjuvant-therapy
- 36cancer.gov/types/breast/patient/triple-negative-breast-cancer-treatment
- 37cancer.gov/types/breast/patient/brca-risk-reduction-surgery
- 38cancer.gov/about-cancer/treatment/recovery/reconstructive-surgery-fact-sheet
- 39cancer.gov/types/breast/patient/breast-conserving-therapy
- 21uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening